At what enterprise value was OPTUM UK acquired in 2026?

During the acquisition of OPTUM UK by TPG in 2026, the company was valued at an estimated revenue multiple of 5x - 12x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b GBP. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of OPTUM UK when it was acquired by TPG?

The estimated EV/EBITDA multiple for OPTUM UK is in the range of Above 20x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was OPTUM UK acquired by TPG?

OPTUM UK was acquired by TPG in 2026.

What was the revenue of OPTUM UK at the time of the deal?

The revenue of OPTUM UK at the time of the deal is estimated to be in the range of 100M - 200M GBP. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of OPTUM UK during the acquisition?

OPTUM UK's EBITDA is estimated to be in the range of 50M - 100M GBP. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the OPTUM UK acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the OPTUM UK deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.reuters.com/business/healthcare-pharmaceuticals/tpg-talks-buy-unitedhealths-optum-uk-unit-sky-news-reports-2026-01-06/

← DATABASE

Home Database Healthcare & PharmaOPTUM UK

01/2026

OPTUM UK acquired by TPG

UNITED KINGDOM Healthcare Services / Health Tech EV 1b - 4b GBP

Context

TPG is in advanced negotiations to acquire Optum UK from UnitedHealth Group. This transaction follows UnitedHealth’s relatively short ownership of the asset, which it acquired in 2023 after an intensive regulatory review by the UK Competition and Markets Authority. The sale process, managed by Bank of America, attracted significant interest from top-tier private equity firms, including Blackstone, reflecting the asset’s status as a high-quality infrastructure-like software provider. The strategic rationale for TPG is a clear "buy-and-build" play, as the firm intends to explore a merger between Optum UK and Nextech, its US-based electronic medical record software provider. Such a combination would create a transatlantic leader in healthcare IT, allowing for the cross-pollination of software features and a broader geographical footprint. For UnitedHealth, the divestment is viewed as a strategic move to optimize its portfolio and improve group valuation by offloading a business that, while dominant in its local market, faced significant regulatory scrutiny regarding vertical integration. The deal is expected to close in early 2026, subject to final negotiations and potential updated reviews by UK health and competition authorities, given the critical nature of the EPR systems provided to the NHS.

OPTUM UK, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Optum UK, primarily comprising the operations of EMIS Group, is the leading provider of healthcare software and electronic patient record (EPR) systems in the United Kingdom. The company’s core business model focuses on supplying mission-critical technology infrastructure to the majority of Britain’s general practitioners (GPs), as well as community pharmacies and hospital departments. Its value proposition centers on the seamless management of clinical data, enabling healthcare professionals to access real-time patient information, streamline administrative workflows, and improve diagnostic accuracy. The group’s strategy is built on high levels of recurring revenue through long-term contracts with the National Health Service (NHS) and related healthcare providers. By acting as the digital backbone of primary care in the UK, Optum UK plays a vital role in the national healthcare ecosystem, facilitating the integration of patient care across different clinical settings and supporting the digital transformation of public health services through advanced data analytics and interoperable software solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
03/2026	RADNET	GLEAMER	FRANCE	Healthcare Services	RadNet acquired Gleamer in an all-cash transaction to integrate its automated diagnostic and reporting solutions into the DeepHealth platform. The acquisition aims to create the world's largest provider of clinical radiology AI solutions by combining RadNet's massive US imaging volume with Gleamer's advanced multi-modality software
03/2026	THERMO FISHER SCIENTIFIC	CLARIO HOLDINGS	UNITED STATES	Healthcare Services	Thermo Fisher Scientific has finalized the acquisition of Clario Holdings, Inc. from a prominent shareholder consortium led by Astorg, Nordic Capital, Novo Holdings, and Cinven. The strategic rationale for this transaction centers on the deep integration of the target's industry-leading endpoint data platform into the group's Laboratory Products and Biopharma Services segment
01/2026	PERMIRA	CARNE GROUP	IRELAND	Healthcare Services	Permira has reached an agreement to acquire a significant minority stake in Carne Group. The transaction facilitates the complete exit of Vitruvian Partners (who invested in 2021) and other minority shareholders
01/2026	SAGARD	QUIPMENT	FRANCE	Healthcare Services	Sagard NewGen acquired a significant minority stake in Quipment, fifteen years after its inception. The deal aims to accelerate Quipment's international expansion, particularly in the US and Asia, and to support its digital transformation
01/2026	ANTIN INFRASTRUCTURE	EMSERE	NETHERLANDS	Healthcare Services	Antin Infrastructure Partners, executing through its Mid Cap Fund I, has entered into a definitive agreement with Dutch family office and investment platform Gryphion to acquire 100% of Emsere. The transaction, which represents the eighth investment completed by Antin's dedicated mid-cap vehicle, is scheduled to close in the first quarter of 2026
11/2025	EURAZEO	EXCELYA	FRANCE	Healthcare Services	The management team of Excelya selected Eurazeo to invest as a minority partner with a ticket composed of a mix of equity (capped at 20%) and quasi-equity instruments, alongside a senior debt package. The transaction facilitated a partial liquidity event for the co-founding partner, who remains a minority shareholder, while providing the company with substantial firepower to pursue further international acquisitions
11/2025	ASKER HEALTHCARE GROUP	FINMED GROUP	FRANCE	Healthcare Services	Asker Healthcare Group has signed a definitive agreement to acquire 80% of the shares in Finmed Group, marking its strategic entry into the French healthcare market. This transaction serves as a platform acquisition, providing the Swedish-based group with a robust foundation to expand its presence in one of Europe's largest medical device markets
10/2025	EVOLEM	APPERTON	FRANCE	Healthcare Services	A French healthcare player specializing in the sterilization of reusable medical equipment has restructured its capital through a secondary MBO. Operating as a mission-critical infrastructure partner within the healthcare sector, the company commands high barriers to entry rooted in stringent clinical regulations and non-discretionary hospital decontamination mandates
05/2025	FIVE ARROWS	HUBLO	FRANCE	Healthcare Services	Hublo enters a new phase of its development by welcoming Five Arrows as its new lead shareholder. This transaction marks a transition from Venture Capital to Private Equity (Primary LBO). The entry of Five Arrows aims to provide Hublo with the strategic and financial resources to consolidate its leadership in France and accelerate its expansion in Europe, particularly in Germany and Northern Europe
04/2025	TRANSCARENT	ACCOLADE	UNITED STATES	Healthcare Services	Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group

REFERENCES

Valuation range: EV 1b - 4b GBP

Revenue range: 100M - 200M GBP

EBITDA range: 50M - 100M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OPTUM UK by TPG are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: optum uk

Acquirer: tpg